BMC Cardiovascular Disorders最新文献

{"title":"Comparison of complete vs. culprit-only revascularization in acute myocardial infarction.","authors":"Ran Chen, Jingping Lu","doi":"10.1186/s12872-025-04777-7","DOIUrl":"https://doi.org/10.1186/s12872-025-04777-7","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis and treatment of acute myocardial infarction (AMI) complicated with multivessel disease (MVD) by percutaneous coronary intervention (PCI) has been well recognized. However, the use of PCI in non-infarct-related coronary arteries remains controversial. We aimed to study the clinical outcome of complete vs. culprit-only revascularization for AMI with MVD before discharge.</p><p><strong>Methods: </strong>173 AMI with MVD who received emergent PCI between January 2013 and December 2018 were retrospectively analyzed. Patients were divided into complete revascularization (CR) group (n = 85) and culprit-only revascularization (COR) group (n = 88). Major adverse cardiovascular and cerebral events (MACCE) at 1, 6, and 12 months after PCI were compared, including recurrent angina, recurrent MI, in-stent thrombosis, new-onset atrial fibrillation (AF), and worsen heart failure (HF).</p><p><strong>Results: </strong>Baseline characteristics of two groups were comparable. There was no significantly statistical difference in MACCE between COR group and CR group, 36.2% vs. 33.3% (P = 0.715), 42.0% vs. 29.7% (p = 0.125) and 44.9% vs. 36.5% (p = 0.304) at 1-, 6- and 12-month follow up respectively. Compared with the CR group, a higher rate of recurrent angina was in COR group (20.3% vs. 5.4%, P = 0.007) at the 6th month. Subgroup analysis showed that hypertensive patients benefited more from complete revascularization at the 6- (OR:0.31, 95%CI: 0.13-0.76) and 12-month (OR:0.38, 95%CI: 0.16-0.90) follow up.</p><p><strong>Conclusions: </strong>Complete revascularization before discharge does not supply additional benefit on long time MACCE as compared with culprit-only intervention strategy in patients presenting with AMI for urgent PCI with multivessel disease.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"325"},"PeriodicalIF":2.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12023691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of inflammatory indexes in in-hospital mortality for patients with acute aortic dissection.","authors":"Yijing Xin, Siqi Lyu, Jingyang Wang, Yimeng Wang, Yuyuan Shu, Hanyang Liang, Yanmin Yang","doi":"10.1186/s12872-025-04775-9","DOIUrl":"https://doi.org/10.1186/s12872-025-04775-9","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study was to assess the relationship between admission inflammatory indexes neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII), and the risk of in-hospital all-cause mortality in acute aortic dissection (AAD) patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 597 AAD patients (Stanford classification: Stanford type A 365 patients, Stanford type B 232 patients) at a single center. Outcomes were the incidence of in-hospital all-cause mortality. The risk of all-cause death was compared between the groups with low and high inflammatory indexes using the Kaplan-Meier curve. The association between admission inflammatory indexes and outcomes was evaluated using the Cox regression model and restricted cubic splines (RCS). Stratified analysis was performed based on AAD type, age (< 50 years or ≥ 50 years), and gender.</p><p><strong>Results: </strong>The Kaplan-Meier curves revealed statistically significant differences in outcomes among the low and high inflammatory indexes groups. Cox regression analysis revealed that the in-hospital mortality risk was significantly high in the high inflammatory index groups. MLR was the strongest associated with in-hospital mortality risk. The RCS curve revealed that NLR was non-linearly and J-shaped correlated with in-hospital mortality, and MLR and SII were linearly correlated with in-hospital mortality. Stratified analysis showed interactions between NLR, MLR, and SII and AAD type and age for the risk of in-hospital mortality.</p><p><strong>Conclusion: </strong>Admission high inflammatory indexes were independently associated with an increased risk of in-hospital all-cause mortality in AAD patients. The inflammatory indexes NLR, MLR, and SII may be useful indicators for predicting in-hospital all-cause mortality in AAD patients.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"323"},"PeriodicalIF":2.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12023605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience.","authors":"Shangsong Shi, Zicheng Ling, Shaohua Gu, Tingbo Jiang, Lin Ling","doi":"10.1186/s12872-025-04767-9","DOIUrl":"https://doi.org/10.1186/s12872-025-04767-9","url":null,"abstract":"<p><strong>Background: </strong>We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>Patients with unstable angina pectoris who underwent PCI from January 2019 to December 2020 were included. All patients were treated with aspirin and ticagrelor as dual antiplatelet therapy and divided into two groups: the eptifibatide + ticagrelor group (180 µg/kg bolus plus 1 µg/kg/min continuous intravenous eptifibatide infusion after PCI for 24 h [n = 152]) and the ticagrelor group (without eptifibatide infusion [n = 152]). Thromboelastography and light transmission aggregometry were used to measure the adenosine diphosphate-induced platelet aggregation rate (PAR). High sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and heart-type fatty acid-binding protein (h-FABP) were measured. In-hospital and 12-month major adverse cardiovascular events (MACEs) and bleeding events were evaluated.</p><p><strong>Results: </strong>The PAR significantly declined at 1, 12, and 24 h after continuous intravenous eptifibatide and returned to the pretreatment level 24 h after discontinuation. All patients in the eptifibatide + ticagrelor group achieved a PAR < 10%. The percentage of patients with a PAR < 10% was significantly higher than in the ticagrelor group (P < 0.001). The increases in hs-TnT (P < 0.001), NT-proBNP (P < 0.05), and h-FABP (P < 0.05) were less pronounced. The eptifibatide + ticagrelor group exhibited lower rates of in-hospital and 12-month myocardial infarction (MI) and in-hospital MACEs (P < 0.05). The rate of bleeding events was not significantly different.</p><p><strong>Conclusion: </strong>Eptifibatide rapidly reduced the PAR in patients with unstable angina pectoris and reduced the rates of MI, in-hospital MACEs, and 12-month MI, without increasing bleeding events. The combined use of eptifibatide and ticagrelor was safe and effective.</p><p><strong>Trial registration: </strong>The registry was registered in the Chinese Clinical Trial Registry (ChiCTR2500096895). The date of registration was 2025-02-08, and it was \"Retrospectively registered\".</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"312"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and internal validation of an OPCABG-specific prediction model for postoperative atrial fibrillation in Chinese patients: a retrospective cohort study.","authors":"Yihan Zheng, Min Zhou, Yiting Lin, Guican Zhang","doi":"10.1186/s12872-025-04780-y","DOIUrl":"https://doi.org/10.1186/s12872-025-04780-y","url":null,"abstract":"<p><strong>Background: </strong>Postoperative atrial fibrillation (POAF) is a common complication after off-pump coronary artery bypass grafting (OPCABG), associated with increased morbidity and healthcare costs. Existing POAF prediction models, developed mainly for Western populations, may not account for genetic, lifestyle, and healthcare disparities in Chinese patients. This study aimed to develop and validate a Chinese-specific nomogram for POAF risk stratification in OPCABG patients.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at a single Chinese center, including 456 consecutive OPCABG patients (2018-2022). Patients were divided into a training set (2018-2021, n = 319) and validation set (2022, n = 137). Multivariable logistic regression with LASSO regularization identified predictors of POAF (occurrence within 7 postoperative days). Model performance was evaluated using C-index, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC).</p><p><strong>Results: </strong>The final nomogram included five independent predictors: age (OR, 1.03), diabetes (OR, 1.85), hypertension (OR, 1.90), previous PCI (OR, 2.51) and last intraoperative blood potassium concentration (OR, 0.30). The model demonstrated excellent discrimination (C-index: 0.809 in training, 0.886 in validation) and good calibration. DCA and CIC showed superior clinical utility compared with existing scores (C2HEST, CHADS2, CHA2DS2-VASc).</p><p><strong>Conclusions: </strong>This OPCABG-specific nomogram outperforms conventional risk scores in predicting POAF in Chinese patients, enabling personalized prophylaxis and resource allocation. External validation in diverse populations is needed to confirm generalizability.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"316"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between inflammatory burden index and risk of heart failure: evidence from NHANES 2003-2017.","authors":"Li-Xin Yun, Wan-Zhong Huang, Changjing He, Yuan Huang, Hua-Feng Yang, Qiang Su, Da-Zhi Lan, Yang-Chun Liu","doi":"10.1186/s12872-025-04781-x","DOIUrl":"https://doi.org/10.1186/s12872-025-04781-x","url":null,"abstract":"<p><strong>Background: </strong>Systemic inflammation contributes to the progression of heart failure (HF). This study aims to investigate the association between inflammatory burden index (IBI) and HF risk.</p><p><strong>Methods: </strong>In this cross-sectional study of NHANES 2003-2017, data from 19,856 participants were analyzed, including 652 participants with HF and 19,204 without HF. Participants were categorized into quartiles based on IBI levels (Q1-Q4). The risk of HF across these quartiles was assessed with adjustment for potential confounders and restricted cubic spline analyses were used to evaluate dose-response relationships.</p><p><strong>Results: </strong>Our results show that participants with HF have higher IBI levels compared to those without HF (2.66 ± 0.27 vs. 1.05 ± 0.03, p < 0.001). The prevalence of HF increases with higher IBI quartiles: Quartile 1 (1.2%), Quartile 2 (1.33%), Quartile 3 (2.60%), and Quartile 4 (4.37%) (p < 0.001). After adjusting for potential confounders, the risk of HF remained elevated across the quartiles: Quartile 2 (odds ratio [OR] = 0.72, 95% confidence interval [CI]: 0.48-1.10), Quartile 3 (OR = 1.06, 95% CI: 0.70-1.61), and Quartile 4 (OR = 1.46, 95% CI: 1.02-2.10) compared to Quartile 1. Restricted cubic spline analysis further confirmed a substantial positive-linear correlation between IBI and HF risk.</p><p><strong>Conclusion: </strong>Higher levels of IBI are related to a high risk of HF, independent of traditional risk factors. These results suggest that IBI could be a useful parameter for identifying individuals at higher risk of HF.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"318"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12023371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in cardiovascular disease outcomes and economic burdens among minorities in southeastern Virginia.","authors":"El Moudden Ismail, Amidi Asra, Sharaf Alddin Reem, Bittner Michael, Zhang Qi","doi":"10.1186/s12872-025-04771-z","DOIUrl":"https://doi.org/10.1186/s12872-025-04771-z","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular diseases are the leading cause of mortality in the United States, presenting significant public health challenges and financial burdens, particularly in Southeastern Virginia, where African American and Hispanic (AA&H) populations are disproportionately affected.</p><p><strong>Methods: </strong>This retrospective observational study analyzed data from 30,855 hospital discharges of AA&H patients across Southeastern Virginia from 2016 to 2020, focusing on individuals aged 18 to 85 with cardiovascular diseases. Utilizing the Virginia Health Information database, we examined demographic information, clinical data, and healthcare utilization patterns through hypothesis tests and regression models to explore associations between these variables and the economic impacts of cardiovascular diseases.</p><p><strong>Results: </strong>Heart failure and shock (47.2% of discharges) and cardiac arrhythmia and conduction disorders (12.3%) were the most prevalent cardiovascular conditions. Female patients incurred significantly higher charges than males across conditions (7.1% higher in heart failure, p < 0.0001; 8.8% higher in chest pain, p < 0.01). Younger patients (< 65 years) faced 8.5% higher charges for cardiac arrhythmia with procedures (p < 0.0001) and 5.2% higher charges for circulatory disorders (p < 0.05). Year of discharge consistently predicted increasing costs (standardized coefficient 0.816 for acute myocardial infarction, p < 0.0001). The presence of fluid and electrolyte disorders was associated with significantly higher charges across conditions (standardized coefficient 0.042 for heart failure, p < 0.0001; 0.051 for acute myocardial infarction, p < 0.0001).</p><p><strong>Discussion: </strong>The findings highlight the complex interplay between demographic characteristics and healthcare costs among AA&H populations, underscoring the need for targeted interventions. The significant economic impact observed calls for culturally competent healthcare strategies that can mitigate high costs and improve health outcomes. However, the retrospective, administrative nature of the data limits establishing causality, with potential misclassification of some conditions.</p><p><strong>Conclusion: </strong>This study provides crucial insights into cardiovascular disease management's demographic and economic dimensions among AA&H populations in Southeastern Virginia. By identifying key factors contributing to healthcare disparities, the research supports the development of tailored interventions aimed at reducing the burden of cardiovascular diseases, thereby improving overall health equity and reducing economic strains on the healthcare system.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"314"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pacing therapy for immune checkpoint inhibitors-associated atrioventricular block: a single-center cohort study.","authors":"Jiaqi Wang, Fanyi Kong, Yifan Wang, Jiaqi Yu, Yingxian Liu, Wei Wu, Yongtai Liu, Peng Gao, Zhongwei Cheng, Kang'an Cheng, Hua Deng, Jinzhi Lai, Jingbo Fan, Lihua Zhang, Quan Fang, Taibo Chen, Deyan Yang","doi":"10.1186/s12872-025-04764-y","DOIUrl":"https://doi.org/10.1186/s12872-025-04764-y","url":null,"abstract":"<p><strong>Background: </strong>ICI-associated myocarditis is an uncommon yet potentially fatal condition, particularly when concomitant with atrioventricular block (AVB) necessitating pacing. The role of pacing therapy for ICI-associated AVB remains unknown.</p><p><strong>Objectives: </strong>The aim of this study is to investigate the efficacy and safety of pacing therapy for ICI-associated AVB.</p><p><strong>Methods: </strong>Patients with ICI-associated myocarditis admitted to Peking Union Medical College Hospital from May 1st 2019 to April 30th 2024 were consecutively screened and the patients with AVB requiring pacing therapy were retrospectively included. Baseline clinical characteristics and initial temporary pacing therapy were evaluated. Follow-up assessments were conducted to evaluate the survival rate and the recovery of atrioventricular conduction.</p><p><strong>Results: </strong>A total of 43 patients with ICI-associated myocarditis were screened. Among them, a total of 11 (11/43, 25.6%) patients (mean age 64.5 ± 8.6 years, female 18.2%) were diagnosed with advanced or complete AVB and subsequently underwent pacing therapy. Short-term (within 90-days after procedure) survival rate was 72.7% (8/11). Atrioventricular conduction recovered in 4 (4/11, 36.4%) patients, without AVB recurrence after temporary pacemaker removal. For safety endpoints, right ventricular (RV) pacing parameters including pacing threshold, sensing amplitude and impedance were acceptable and no procedure-related complications occurred except RV temporary active fixation lead dislodgement in 1 patient (1/11, 9.1%). No pacing system related-infection occurred.</p><p><strong>Conclusions: </strong>Pacing therapy for ICI-associated AVB demonstrates both safety and efficacy. ICI-associated AVB shows a high rate of recovery. Temporary pacemaker with active fixation lead may be a reasonable option for the initial pacing therapy.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"319"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12023490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between S100A12 and risk of peripheral arterial disease in patients with dyslipidemia: a cross-sectional study.","authors":"Wenyu Cai, Yilin He, Guohua Li, Dengqing Zhang, Zimin Chen, Shijia Jin, Yifan Zhang, Zhong Chen","doi":"10.1186/s12872-025-04752-2","DOIUrl":"https://doi.org/10.1186/s12872-025-04752-2","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;S100A12 acts as a pro-inflammatory agent in vivo, with a close relationship with plaque formation in patients with acute coronary syndrome (ACS), end-stage renal disease, and diabetes. Peripheral arterial disease (PAD) can lead to mobility difficulties and ultimately disability and amputation. The association between S100A12 and risk of peripheral arterial disease remains unclear. This study aims to investigate the association between S100A12 and the risk of PAD in patients with dyslipidemia.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;From March 2023 to June 2024, 478 patients were included in this cross-sectional study. They were divided into PAD group (n = 105) and control group (n = 373) according to the presence or absence of PAD (The diagnosis of PAD is a combination of the patient's clinical symptoms, imaging evidence and ankle-brachial index). Plasma S100A12 was detected by available kit. General information, disease history, smoking history, and laboratory indicators were collected from both groups. The relationship between S100A12 and the risk of PAD was analyzed using statistical methods.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Levels of S100A12 were significantly higher in the PAD group of dyslipidemia [0.22 (0.13,1.49) ng/cL vs. 0.13 (0.10,0.18)ng/cL, p value &lt; 0.001]. Univariate and multivariate logistic regression analyses suggested that the risk of PAD was significantly higher with increasing levels of S100A12 [Odd ratio (OR) (95%CI) = 2.264 (1.681, 3.047), p value &lt; 0.05]. In addition, lower high-density lipoprotein cholesterol (HDL-C) level and diabetes mellitus (DM) were independent risk factors for PAD [OR (95%CI) = 0.388 (0.186,0.809), p value = 0.012; OR = 2.375 (1.527,3.695), p value &lt; 0.001]. Subgroup analysis suggested that S100A12 was significantly and positively associated with the risk of PAD in all subgroups, regardless of whether HDL-C levels &lt; 1.03 mmol/L, age &gt; 60 years, and presence of diabetes or hypertension. Restricted cubic spline (RCS) curves suggested that the correlation between S100A12 and the risk of PAD was nonlinear (p-non-linear value &lt; 0.05). The RCS curves showed that the positive correlation between S100A12 and the risk of PAD was stronger when the S100A12 level was less than 1.00ng/cL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In conclusion, elevated S100A12 level is an independent risk factor for PAD in patients with dyslipidemia. In different subgroups, S100A12 was significantly and positively associated with the risk of PAD after adjusting for different factors. There is a non-linear relationship between S100A12 and the risk of PAD, with a stronger positive correlation at S100A12 levels below 1.00ng/cL. These findings implied that S100A12 is a potential biomarker for identifying patients with dyslipidemia who are at high risk of developing PAD. They also implied that S100A12 levels can be routinely monitored in dyslipidemic populations for the early detection of PAD and to guide the manageme","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"313"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computed tomography-based coronary lumen volume to myocardial mass ratio in patients undergoing transcatheter aortic valve replacement: a novel method for risk assessment.","authors":"Wenting Li, Ruichen Ren, Qingyuan Zhao, Chengcheng Qi, Zhiyu Chen, Yang Zhang","doi":"10.1186/s12872-025-04705-9","DOIUrl":"https://doi.org/10.1186/s12872-025-04705-9","url":null,"abstract":"<p><strong>Background: </strong>The coronary lumen volume to myocardial mass (V/M) ratio has been suggested as a quantitative metric of potential imbalance between coronary blood supply and myocardial oxygen demand. This study was designed to assess the prognostic value of the V/M ratio for predicting major adverse cardiovascular events (MACE) in patients undergoing transcatheter aortic valve replacement (TAVR).</p><p><strong>Methods: </strong>This study enrolled patients who received a standard planning computed tomography (CT) scan before TAVR and dichotomized at the median of 33.31 mm³/g of V/M ratio into groups with low V/M ratio and high V/M ratio. The V/M ratio was calculated by coronary computed tomography angiography (CTA). The endpoint was a composite of all-cause mortality, stroke, and hospitalization for heart failure. The cumulative incidence of the MACE was compared using Kaplan-Meyer plots and uni- and multivariate Cox proportional hazards regression analysis.</p><p><strong>Results: </strong>In total, 139 patients were enrolled in this study finally (mean age 71.7 ± 6.7 years, 41.7% female). The mean V/M ratio was considerably lower in patients with MACE than in those without MACE (26.5 ± 4.9mm³/g vs. 34.0 ± 3.8mm³/g, P<0.001). Multivariate Cox proportional hazards regression showed that the low V/M ratio group (≤ 33.31 mm³/g) had a higher risk of MACE after TAVR (HR: 6.14, 95%CI: 1.37-27.54; P = 0.018).</p><p><strong>Conclusions: </strong>The lower V/M ratio could serve as an independent predictor of MACE in patients undergoing TAVR.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"311"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between hemoglobin glycation index and all-cause mortality in ill critically patients with heart failure: a retrospective study in MIMIC-IV database.","authors":"Yulong Wang, Shanshan Tang, Haokun Liu, Yongle Li","doi":"10.1186/s12872-025-04711-x","DOIUrl":"https://doi.org/10.1186/s12872-025-04711-x","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a major cause of mortality in critically ill patients and often requires intensive care. The hemoglobin glycation index (HGI), defined as the difference between predicted glycated hemoglobin (HbA1c) and measured HbA1c, may provide additional prognostic insights beyond traditional glycemic metrics.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 8,098 adult patients with HF from the MIMIC-IV database (2008-2022). All were first-time ICU admissions with available hematologic and metabolic data. Patients were stratified into three groups (T1 ≤ - 1.26, - 1.26 < T2 < 1.74, T3 ≥ 1.74) based on HGI. Baseline characteristics were recorded within 24 h of ICU admission, including demographic data, disease severity scores, comorbidities, and medication use. Logistic regression and Cox proportional hazards models assessed the associations between HGI and in-hospital, 30-day, and 1-year all-cause mortality, adjusting for age, sex, race, comorbidities, laboratory results, and relevant treatments. Restricted cubic spline (RCS) analysis was performed to examine potential non-linear relationships. We used sensitivity analyses to increase the confidence in our primary outcome.</p><p><strong>Results: </strong>Patients in the lowest HGI group (T1) had significantly higher in-hospital, 30-day, and 1-year mortality than those in the other two groups. Specifically, T1 showed an 18.6% in-hospital mortality rate, compared with 12.3% and 9.7% in T2 and T3, respectively (p < 0.001). Fully adjusted models revealed that each 1-unit increase in HGI was associated with an approximate 12% reduction in in-hospital mortality risk (OR = 0.88; 95%CI: 0.83-0.93), and an 3% decreased risk of 1-year all-cause mortality (HR 0.97; 95%CI0.94~1.00). RCS analysis indicated a J-shaped relationship between HGI and mortality, underscoring the heightened risk associated with very low HGI. We conducted sensitivity analyses by separately excluding missing data, diagnosed sepsis, and diagnosed hepatic impairment, consistent with the primary analysis.</p><p><strong>Conclusions: </strong>In critically ill HF patients, extremely low HGI levels correlate with poorer short- and long-term survival. These findings suggest that HGI could serve as an adjunct risk stratification tool, prompting closer monitoring and potential intervention in patients with markedly low HGI.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"317"},"PeriodicalIF":2.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}